medigraphic.com

2008, Número 3

<< Anterior Siguiente >>

Rev Med Hosp Gen Mex 2008; 71 (3)


Linfomas no Hodgkin de nariz, paladar y orofaringe en pacientes del Hospital General de México

Romero GMB, Lazos OM, Cruz OH, Vázquez HP, Cruz AAL, Velásquez G, Rivas VS, Feller AC

Idioma: Español
Referencias bibliográficas: 78
Paginas: 119-125
Archivo PDF: 427.25 Kb.


RESUMEN

Los linfomas de cavidad nasal, paladar y orofaringe comprenden un grupo heterogéneo de entidades con cuadro clínico semejante y comportamiento biológico diferente. Son poco frecuentes en Europa, Estados Unidos y comunes en Asia, así como en algunos países de América Latina, incluyendo México. Se estudiaron 43 casos. El área más afectada fue la cavidad nasal con 28 casos (65.2%), paladar siete (16.2%), orofaringe siete (16.2%) y un caso en el seno maxilar (2.3%). Los pacientes con linfomas nasales presentaron: obstrucción, epistaxis, rinorrea, dolor y sensación de masa tumoral; los de paladar: dolor, odinofagia y disfagia. Dos pacientes fueron HIV positivos. Veintisiete (62.7%) presentaron estadio clínico avanzado (etapas III y IV). Se identificaron 28 (65.2%) linfomas T/NK (natural killer); fueron de tipo blástico, pleomórfico y de células medianas y grandes, con cantidades variables de necrosis, angioinvasión y angiodestrucción. Los linfomas B correspondieron al 34.8% (15 casos); siete (46.6%) fueron difusos de células grandes, con núcleos lobulados y células anaplásicas; cinco (33.3%) presentaron células de citoplasma claro, uno células blásticas y dos (13.3%) no pudieron clasificarse. Los linfomas T/NK fueron los más frecuentes en nuestro medio con afección de las fosas nasales. La edad promedio de los pacientes fue de 42.4 años, sin predominio de sexo; los linfomas B predominaron en paladar y orofaringe, con una edad promedio de 64.4 años y con mayor afección del sexo masculino. El estadio clínico inicial al momento del diagnóstico en ambos grupos fue en etapas clínicas III y IV.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McBride P. Photographs of a case of rapid destruction of the nose and face. J Laryngol Rhinol 1897; 12: 64-67.

  2. Harris NL, Jaffe ES, Diebold J et al. World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.

  3. Cheung MMC, Chan JKC, Lau CWH et al. Primary non-Hodgkin´s lymphoma of the nose and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-77.

  4. Kwong YL, Chan ACL, Liang R, Chang AKS, Chim CS, Chan TK. CD 56 NK lymphomas: Clinicopathological features and prognosis. Brit J of Haematol 1997:97; 821-829.

  5. Liang R, Todd D, Chan TK, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995; 13: 666-670.

  6. Arber DA, Weiss LM, Albujar PF, Chen YY, Jaffe ES. Nasal lymphomas in Peru: High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993; 17: 392-399.

  7. Chang KL, Chen Y, Shibata D et al. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diag Mol Pathol 1992; 1: 246-255.

  8. Gutiérrez RM, Rivas GMR, González CR. Linfoma de fosas nasales. Revisión de 62 casos. Rev Invest Clin (Mex) 1984; 36: 1-6.

  9. Meneses GA, Súchil-Bernal L, de la Garza-Salazar J, Gómez-González E. Linfomas angiocéntricos centrofaciales de células T/NK. Aspectos histopatológicos y algunas consideraciones clínicas de 30 pacientes del Instituto Nacional de Cancerología, México. Cir Ciruj 2002; 70: 410-416.

  10. Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, Krenacs L, Kingma WD, Raffeld M, Jaffe SE. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Modern Pathol 1998; 11: 754-761.

  11. Quintanilla-Martínez L, Kremer M, Keller G, Nathrath M, Gamboa-Dominguez A, Meneses A, Luna-Contreras L et al. P 53 mutations in nasal natural killer/T-cell lymphoma from Mexico. Association with large cell morphology and advanced disease. Am J of Pathol 2001; 159 (6): 2095-2015.

  12. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT et al. P 53 mutation in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocitic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413-5417.

  13. Cheung MMC, Chan JKC, Lau WH et al. Primary non-Hodgkin´s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-77.

  14. Jaffe ES, Chan JKC, Su IH et al. Report of the workshop on nasal and related extranodal angiocentric T/natural Killer cell lymphomas: Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103-111.

  15. Quintanilla-Martínez L, Franklin JL, Guerrero I et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru; high prevalence of p53 expression. Human Pathol 1997; 28: 849-851.

  16. Chan JKC, Ng CS, Tsang WYW. Nasal/nasopharyngeal lymphomas: An immunohistochemical analysis of 57 cases on frozen tissues. Mod Pathol 1993; 6: 87 (abst).

  17. Suzumiya J, Takeshita M, Kimura N et al. Expression of adult and fetal natural killer makers in sinunasal lymphomas. Blood 1994; 83: 2255-2260.

  18. Abbondanzo SL, Wenig BM. Non Hodgkin´s lymphoma of the sinunasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer 1995; 75: 1281-1291.

  19. Fellbaum C, Hansmann ML, Lennert K. Malignant lymphomas of the nasal cavity and paranasal sinuses. Virchows Arch A 1989; 414: 399-405.

  20. Seidell J. Obesity, insulin resistance and diabetes-a worldwide epidemia. Br J Nutr 2000; 83 (suppl 1): s5-s8.

  21. Must A, Spadano J, Coakley E, Field A, Colditz G, Dietz W. The disease burden associated with overweight and obesity. Am J Clin Nutr 1997; 66: 551-556.

  22. Gao Y, Yang Q, Zhou J, Chen L. Association between leptin, insulin, and body fat distribution in 2-diabetes mellitus. Ann N Y Acad Sci 2000; 904: 542-545.

  23. Lillioja S, Mott DM, Spraul M, ferraro R, Foley JE, Ravussin E, Knowler WC, Bennet PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 1988-1992.

  24. Sinaiko AR, Donahue RP, Jacobs DR Jr, Prineas RJ. Relation of weight and rate of increase in weight during childhood and adolescent to body size, blood pressure, fasting insulin, and lipids in young adults. The Minneapolis Children´s Blood Pressure Study. Circulation 1999; 99: 1471-1476.

  25. Haffner S. Metabolic syndrome, diabetes and coronary heart disease. Int J Clin Pract 2002; suppl: 31-37.

  26. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108: 1541-1545.

  27. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci 2003; 73: 2395-2411.

  28. Kereiakes D, Willerson J. Metabolic syndrome epidemic. Circulation 2003; 108: 1552-1553.

  29. Grundy SM. Multifactorial causation of obesity: Implications for prevention. Am J Clin Nutr 1998; 67: 563S-572s.

  30. Hodge AM, Zimmet PZ. The epidemiology of obesity. Baillieres Clin Endocrinol Metab 1994; 8: 577-599.

  31. Karter A, Mayer-Davis E, Selby J, D’Agostino T, Haffner S, Sholinsky P, Bergman R, Saad M, Hamman R. Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women, The Insulin Resistance and Atherosclerosis Study. Diabetes 1996; 45: 1547-1555.

  32. Linderman R, Romero L, Hundley R, Allen A, Liang H, Baumgartner R, Koehler K, Schade D, Garry P. Prevalences of type 2 diabetes, the insulin resistance syndrome, and coronary heart disease in an elderly, biethnic population. Diabetes Care 1998; 21: 959-966.

  33. Thomas G, Critchley J, Tomlinson B, Anderson P, Lee Z, Chan J. Obesity, independent of insulin resistance, is a major determinant of blood pressure in normoglycemic Hong Kong Chinese. Metabolism 2000; 49: 1523-1528.

  34. Mc Keigue P. Metabolic consequences of obesity and body fat pattern: Lessons from migrant studies. Ciba Found Symp 1996; 201: 54-64.

  35. Phillips DI, Barker DJ, Hales CN, Hirst S, Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia 1994; 37: 150-154.

  36. Barker DJ. The intrauterine environment and adult cardiovascular disease. Ciba Found Symp 1991; 156: 3-10.

  37. Barker DJ. Fetal growth and adult disease. Br J Obstet Gynaecol 1992; 99: 275-276.

  38. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 1992; 35: 595-601.

  39. Omran ER. The epidemiologic transition. A theory of epidemiology of population change. Milbank Mem Fund Q 1971; 49: 509-538.

  40. Frenk J, Frejka T, Bobadilla JL, Stern C, Lozano R, Sepulveda J, Jose M. The epidemiologic transition in Latin America. Bol Oficina Sanit Panam 1991; 111: 485-496.

  41. Rivera-Dommarco J, Barquera S, Campirano F, Campos-Nonato I, Safdie M, Tovar V. The epidemiological and nutritional transition in México: Rapid increase of non-communicable chronic diseases and obesity. Public Health Nutr 2002; 14: 113-122.

  42. Arellano S, Bastarrachea R, Bourges H. La obesidad en Mexico. Rev Endocrinol Nutr 2004; 12: 580-587.

  43. Phillips DR. Urbanization and human health. Parasitology 1993; 106 (suppl): S93-s107.

  44. Sepulveda-Amor J, Lezana MA, Tapia-Conyer R, Valdespino JL, Madrigal H, Kumate J. Nutritional status of preschool children and women in México: results of a probabilistic national survey. Gac Med Mex 1990; 126: 207-224.

  45. Olaiz G, Rojas R, Barquera S. Encuesta Nacional de Salud 2000. La salud de los adultos 2003. Instituto Nacional de Salud Pública. 2003. p. 36-46.

  46. Hernandez-Diaz S, Peterson K, Dixit S, Hernandez B, Parra S, Barquera S, Sepulveda J, Rivera J. Association of maternal short stature with stunting in Mexican children:common genes vs environment. Eur J Clin Nutr 1999; 53: 938-945.

  47. Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K, Clark PM. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X:(relation to reduced fetal growth. Diabetologia 1993; 36: 62-67.

  48. Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. Br Med J 1993; 306: 422-426.

  49. Barker DJ, Clark PM. Fetal undernutrition and disease in later life. Rev Reprod 1997; 2: 105-112.

  50. Barker DJ. The long-term outcome of retarded fetal growth. Clin Obstet Gynecol 1997; 40: 853-863.

  51. Haffner SM, Miettnem H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092.

  52. Secretaría de Salud. Encuesta nacional de Enfermedades Crónicas. México, DF: Dirección de Epidemiología-Secretaría de Salud; 1993.

  53. Barquera S, Rivera –Dommarco J, Espinosa-Montero J, Safdie M, Campirano F, Monterrubio E. Energy and nutrient consumption in Mexican women 12-49 years of age: Analysis of the National Nutrition Survey 1999. Sal Pub Mex 2003; 45: s530-s539.

  54. Rivera-Dommarco J, Shama-Lavy T, Villalpando-Hernández E, Rivera-Pasquel M, Cuevas-Nasu L, Mejía-Rodríguez F, Barquera S. Prescolares. En: Rivera-Dommarco J, Shamah-Levy T, Villalpando S, González-Cossio T, Hernández-Prado B, Sepúlveda-Amor J (eds). Encuesta Nacional de Nutrición 1999. Estado nutricio de niños y mujeres de México. Cuernavaca, Mor: Instituto Nacional de Salud Pública; 2000. p. 29-61.

  55. Rivera-Dommarco JA, Monterrubio EA, González–Cossio T, García-Feregrino R, García-Guerra A, Sepúlveda-Amor J. Nutritional status of indigenous children younger than five years of age in México: Results of a national probabilistic survey. Sal Pub Mex 2003; 45: s466-s476.

  56. Aguilar-Salinas CA, Olaiz G, Valles V, Rios-Torres JM, Gomez-Perez J, Rojas R, Franco A, Sepúlveda J. High prevalence of low HDL cholesterol concentrations and miexed hyperlipidemia in a Mexican nationwide survey. J Lippid Res 2001; 42: 1298-1307.

  57. Valles V, Aguilar-Salinas C, Gomez-Perez FJ, Rojas R, Franco A, Olaiz G, Rull JA, Sepulveda J. Apolipoprotein B and A-I distribution in the Mexican urban adults. Results of a nationwide survey. Metabolism 2002; 51: 560-568.

  58. WHO. Physical status: The use and interpretation of anthropometry. Geneva: World Health Organization; 1995.

  59. Metthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.

  60. Isomaa B, Lahti K, Almgren P, Nissen M, Tinamaija T, Taskinen M, Forsen B, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.

  61. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 287: 356-359.

  62. American Obesity Association. Guidance for treatment of adult obesity. AOA – Shape up America; 1996.

  63. American Obesity Association. Standards of medical care in diabetes. Diabetes Care 2004; 27: s15-s35.

  64. Sacks D, Bruns D, Goldstein D, Maclaren M, McDonald J, Parrot M. Guideliness and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436-472.

  65. Valdes-Salgado R, Hernandez AM, Sepulveda AJ. Tobacco use in the region of the Americas: Elements for a program of action. Sal Pub Mex 2002; 44 (supl 1): S125-135.

  66. SPSS. SPSS for Windows. Relase 10.0.0. Chicago, SPSS Inc, 1999.

  67. Stata Corp. Stata reference manual. Relase 7. Collage Station, TX. Stata Press, 2001.

  68. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M. Metabolic syndrome: Epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003; 27: 1283-1289.

  69. Fernandez J, Allison D. Understanding racial differences in obesity and metabolic syndrome traits. Nutr Rev 2003; 61: 316-319.

  70. Shen B, Todaro J, Niaura R, Mc Caffery J, Zhang J, Spiro A, Ward K. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003; 157: 701-711.

  71. Choi K, Lee J, Kim K, Kim D, Kim S, Shin D, Kim N, Park I, Coi D, Baik S. Factor analysis of the metabolic syndrome among elderly Koreans-the South-West Seoul Study. Diabet Med 2003; 20: 99-104.

  72. Carr M. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404-2411.

  73. Irwin M, Ainsworth B, Mayer-Davis E, Addy C, Pate R, Durstine J. Physical activity and the metabolic syndrome in a triethnic sample of women. Obes Res 2002; 10: 1030-1037.

  74. NHLBI Obesity Education Initiative Expert Panel. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. Obes Res 1998; 6: 51s-209s.

  75. Park Y, Zhu S, Palaniappan L, Heshka S, Carnethon M, Heymsfield S. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health an Nutrition Examination Survey, 1998-1994. Arch Intern Med 2003; 163: 427-436.

  76. Meigs J, Wilson P, Nathan D, D’Angostino R, Williams K, Haffner S. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003; 52: 2160-2167.

  77. Carnethon MR, Fortman SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk Factors for Progression to Incident Hyperinsulinemia: The Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol 2003; 158: 1058-1067.

  78. Kopp W. High-insulinogenic nutrition-an etiologic factor for obesity and the metabolic syndrome? Metabolism 2003; 52: 840-844.




2020     |     www.medigraphic.com